4.7 Review

Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance

Journal

BIOMEDICINES
Volume 9, Issue 8, Pages -

Publisher

MDPI
DOI: 10.3390/biomedicines9080852

Keywords

Cu homeostasis; cancer; Cu overload; Cu chelators; Cu ionophores; Cu toxicity; chemical biology; thiosemicarbazones; clinical trials; immune system

Funding

  1. City University of Hong Kong [7200682, 9610518]

Ask authors/readers for more resources

Copper plays a crucial role in cellular growth and development and its imbalance can lead to toxicity. This review explores the mechanisms of intracellular copper balance interference in tumor development and progression, and discusses the potential of using copper-depleting and copper-overloading conditions for improved patient outcomes. Additionally, the advantages of pre-formed copper complexes in comparison to in situ formed complexes are highlighted.
Copper (Cu) is a vital element required for cellular growth and development; however, even slight changes in its homeostasis might lead to severe toxicity and deleterious medical conditions. Cancer patients are typically associated with higher Cu content in serum and tumor tissues, indicating increased demand of cancer cells for this micronutrient. Cu is known to readily cycle between the +1 and +2 oxidation state in biological systems. The mechanism of action of Cu complexes is typically based on their redox activity and induction of reactive oxygen species (ROS), leading to deadly oxidative stress. However, there are a number of other biomolecular mechanisms beyond ROS generation that contribute to the activity of anticancer Cu drug candidates. In this review, we discuss how interfering with intracellular Cu balance via either diet modification or addition of inorganic Cu supplements or Cu-modulating compounds affects tumor development, progression, and sensitivity to treatment modalities. We aim to provide the rationale for the use of Cu-depleting and Cu-overloading conditions to generate the best possible patient outcome with minimal toxicity. We also discuss the advantages of the use of pre-formed Cu complexes, such as Cu-(bis)thiosemicarbazones or Cu-N-heterocyclic thiosemicarbazones, in comparison with the in situ formed Cu complexes with metal-binding ligands. In this review, we summarize available clinical and mechanistic data on clinically relevant anticancer drug candidates, including Cu supplements, Cu chelators, Cu ionophores, and Cu complexes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available